Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

IMPORTANCE: There are no specifically approved targeted therapies for the most common genomically defined subset of non–small cell lung cancer (NSCLC), KRAS-mutant lung cancer. OBJECTIVE: To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib + docetaxel with...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA
Asıl Yazarlar: Jänne, Pasi A., van den Heuvel, Michel M., Barlesi, Fabrice, Cobo, Manuel, Mazieres, Julien, Crinò, Lucio, Orlov, Sergey, Blackhall, Fiona, Wolf, Juergen, Garrido, Pilar, Poltoratskiy, Artem, Mariani, Gabriella, Ghiorghiu, Dana, Kilgour, Elaine, Smith, Paul, Kohlmann, Alexander, Carlile, David J., Lawrence, David, Bowen, Karin, Vansteenkiste, Johan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2017
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815037/
https://ncbi.nlm.nih.gov/pubmed/28492898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2017.3438
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller